

Applicants: Norman Latov and Armin Alaedini  
U.S. Serial No.: 09/825,572  
Filed: April 3, 2001  
Page 2

Please amend the subject application as follows:

In the Claims

Please cancel claims 13, 23, 24, and 25 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a continuation or other application.

Please amend claims 1, 4, 9, 20, and 26 as follows:

- A1
1. (Amended) A method of detecting antibodies in a blood or blood derivative solution comprising:
    - a) contacting the blood or blood derivative solution with a ganglioside-coated surface of a sensor chip under conditions that permit the antibodies to bind to the ganglioside coating;
    - b) detecting a change in surface plasmon resonance signal of the sensor chip resulting from the antibodies binding to the ganglioside coating.

- A2
2. (Amended) The method of claim 1, wherein the antibody is an anti-ganglioside antibody.

- A3
3. (Amended) The method of claim 1, wherein the control antigen is Ganglioside GM2.

- A4
- 10  
20. (Amended) The method of claim 1, wherein the surface plasmon resonance signal is increased by washing the solution from the surface of the sensor chip and applying a second solution containing a secondary antibody to the
- A

A4 con's surface.

- A5 ¶ 26. (Amended) The method of claim 27, wherein the disease is Guillian-Barré syndrome, motor neuropathy, peripheral neuropathy, or an autoimmune neuropathy.

Please add new claim 27 as follows:

- A6 ¶ 27. (New) A method of determining whether a subject is suffering from a neurological disease comprising:
- a) contacting the solution with a sensor chip comprising a ganglioside coated surface under conditions that permit anti-ganglioside antibodies to bind to the ganglioside coating and the sensor chip to emit a surface plasmon resonance signal; and
  - b) detecting a change in the surface plasmon resonance signal emitted by the sensor chip so as to thereby detect the binding of the antibodies to the ganglioside coating,
- wherein detection of the change in surface plasmon resonance signal indicates the subject is suffering from the neurological disease.

A mark-up copy of the claims is annexed hereto as **Exhibit A**.

REMARKS

Claims 1-26 are pending in the subject application, with claims 2, 3, 5, 8, 15-19, 21, and 22 withdrawn from consideration. Applicants

7